HRP20200662T1 - Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak - Google Patents
Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak Download PDFInfo
- Publication number
- HRP20200662T1 HRP20200662T1 HRP20200662TT HRP20200662T HRP20200662T1 HR P20200662 T1 HRP20200662 T1 HR P20200662T1 HR P20200662T T HRP20200662T T HR P20200662TT HR P20200662 T HRP20200662 T HR P20200662T HR P20200662 T1 HRP20200662 T1 HR P20200662T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical preparation
- axl
- cancer
- ylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Farmaceutski pripravak za uporabu u postupku liječenja raka povezanog s AXL-om, koji sadrži 6-etil-3-({3-metoksi-4-[4-(4-metilpiperazin-l-il)piperidin-l-il]fenil}amino)-5-(tetrahidro-2H-piran-4-ilamino)pirazin-2-karboksamid ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv ekscipijent, naznačen time što rak povezan s AXL-om je rak koji je stekao otpornost aktiviranjem AXL-a nasuprot terapiji sa antikancerogenim sredstvom.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što rak povezan s AXL-om je rak s visokom ekspresijom AXL-a.
3. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što je rak koji je stekao otpornost aktiviranjem AXL-a nasuprot terapiji sa antikancerogenim sredstvom nesitnostanični rak pluća s aktivirajućim mutacijama EGFR-a, koji je stekao otpornost na terapiju s inhibitorom EGFR tirozin kinaze.
4. Farmaceutski pripravak za uporabu prema zahtjevu 3, koji se upotrebljava u kombinaciji s inhibitorom EGFR tirozin kinaze.
5. Farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time što inhibitor EGFR tirozin kinaze je inhibitor EGFR tirozin kinaze odabran iz skupine koja sadrži erlotinib, gefitinib i lapatinib.
6. Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time što je inhibitor EGFR tirozin kinaze erlotinib.
7. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time što 6-etil-3-({3-metoksi-4-[4-(4-metilpiperazin-l-il)piperidin-l-il]fenil}amino)-5-(tetrahidro-2H-piran-4-ilamino)pirazin-2-karboksamid ili njegova farmaceutski prihvatljiva sol je 6-etil-3-({3-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il] fenil}amino)-5-(tetrahidro-2H-piran-4-ilamino)pirazin-2-karboksamid.
8. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time što 6-etil-3-({3-metoksi-4-[4-(4-metilpiperazin-l-il)piperidin-l-il]fenil}amino)-5- (tetrahidro-2H-piran-4-ilamino)pirazin-2-karboksamid ili njegova farmaceutski prihvatljiva sol je 6-etil-3-({3-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il] fenil}amino)-5-(tetrahidro-2H-piran-4-ilamino)pirazin-2-karboksamid hemifumarat.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
| EP15746276.3A EP3103453B1 (en) | 2014-02-04 | 2015-02-03 | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200662T1 true HRP20200662T1 (hr) | 2020-10-02 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200662TT HRP20200662T1 (hr) | 2014-02-04 | 2015-02-03 | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (hr) |
| EP (1) | EP3103453B1 (hr) |
| JP (1) | JP6390626B2 (hr) |
| KR (1) | KR102322338B1 (hr) |
| CN (3) | CN113425727A (hr) |
| AU (1) | AU2015215578B2 (hr) |
| BR (1) | BR112016017897A8 (hr) |
| CA (1) | CA2938818C (hr) |
| CY (1) | CY1122968T1 (hr) |
| DK (1) | DK3103453T3 (hr) |
| EA (1) | EA033304B1 (hr) |
| ES (1) | ES2788390T3 (hr) |
| HR (1) | HRP20200662T1 (hr) |
| HU (1) | HUE049437T2 (hr) |
| IL (1) | IL247077B (hr) |
| LT (1) | LT3103453T (hr) |
| ME (1) | ME03775B (hr) |
| MX (1) | MX363543B (hr) |
| MY (1) | MY193536A (hr) |
| PH (1) | PH12016501527B1 (hr) |
| PL (1) | PL3103453T3 (hr) |
| PT (1) | PT3103453T (hr) |
| RS (1) | RS60150B1 (hr) |
| SG (1) | SG11201606413RA (hr) |
| SI (1) | SI3103453T1 (hr) |
| SM (1) | SMT202000214T1 (hr) |
| TW (1) | TWI655945B (hr) |
| UA (1) | UA120607C2 (hr) |
| WO (1) | WO2015119122A1 (hr) |
| ZA (1) | ZA201605379B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3103453T3 (da) * | 2014-02-04 | 2020-04-20 | Astellas Pharma Inc | Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel |
| EP3318259B1 (en) | 2015-07-03 | 2023-01-11 | Astellas Pharma Inc. | Stable pharmaceutical composition for oral administration |
| ES2894691T3 (es) * | 2015-11-04 | 2022-02-15 | Astellas Pharma Inc | Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202304908A (zh) * | 2021-04-14 | 2023-02-01 | 日商衛材R&D企管股份有限公司 | 四氫吡啶并嘧啶化合物 |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009215168A1 (en) * | 2008-02-12 | 2009-08-20 | Dana-Farber Cancer Institute | Fish assay for EML4 and ALK fusion in lung cancer |
| CN102036990B (zh) * | 2008-03-19 | 2015-09-30 | 凯姆桥公司 | 新型酪氨酸激酶抑制剂 |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| PT3009428T (pt) | 2009-05-08 | 2018-04-02 | Astellas Pharma Inc | Composto diamino-carboxamida heterocíclico |
| CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| WO2013078271A1 (en) * | 2011-11-21 | 2013-05-30 | Immunogen, Inc. | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| UA113204C2 (xx) * | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| ES2700231T3 (es) * | 2012-11-21 | 2019-02-14 | Janssen Biotech Inc | Anticuerpos de EGFR/c-Met biespecíficos |
| DK3103453T3 (da) * | 2014-02-04 | 2020-04-20 | Astellas Pharma Inc | Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| EP3318259B1 (en) * | 2015-07-03 | 2023-01-11 | Astellas Pharma Inc. | Stable pharmaceutical composition for oral administration |
-
2015
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active Active
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja active Application Filing
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 SM SM20200214T patent/SMT202000214T1/it unknown
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt not_active Application Discontinuation
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527B1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200662T1 (hr) | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak | |
| ZA202109164B (en) | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| CY1121698T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
| HRP20180804T1 (hr) | Inhibitori dnk-pk | |
| SG10201805033XA (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| MY187555A (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| PH12017502236A1 (en) | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors | |
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| MX373042B (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| PH12016502461A1 (en) | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts | |
| MX2016004936A (es) | Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| MX2015017512A (es) | Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| MX2015008502A (es) | Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| CY1123527T1 (el) | Αντιφυματικος παραγοντας | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| MX386804B (es) | Derivados de tetrahidroquinolina como antagonistas del receptor p2x7. | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |